A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease
Completed · Phase 3 · NCT02620046
Conditions: Colitis, Ulcerative, Crohn's Disease
At a glance
- Research payments reported, 2025
- $126,521
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 746
About the trial
- Sponsor
- Takeda
- Tested
- Vedolizumab SC (drug)
- Dates
- Started 2016-04-15; completion 2024-06-12
- Results posted
- Yes
The main aim of the study is to check for long-term side effects of Vedolizumab Subcutaneous (also known as Vedolizumab SC) in people with ulcerative colitis (UC) and Crohn's disease (CD). Vedolizumab SC will be given as an injection just under the skin. This type of injection is called a subcutaneous injection or SC for short. Another aim of the study is to collect information on whether the participant's condition remains under control or improves during and after treatment with Vedolizumab SC. Participants who previously took part in studies MLN0002SC-3027 or MLN0002SC-3031 will be invited to visit the study clinic. At this visit, the study doctor will check if each participant can tak…
From ClinicalTrials.gov, last updated 2025-04-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Takeda Pharmaceuticals U.S.A., Inc. reported $126,521 in research payments for this study in 2025 (116 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Raymond W. Phillips, M.D. Specialist · Naples, FL
- Douglas C. Wolf, MD Gastroenterology · Atlanta, GA
- Joseph D. Frasca, M.D. Gastroenterology · Chicago, IL
- Michael Barker JR., MD Gastroenterology · Baton Rouge, LA
- Ziad H. Younes, M.D. Gastroenterology · Germantown, TN
- Jeff Bullock, M.D. Gastroenterology · San Antonio, TX
- Timothy L. Zisman, MD, MPH Gastroenterology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Gi Pros Inc $45,014
- Gastro One $38,735
- Texas Digestive Disease Consultants PLLC $24,050
- Rush University Medical Center, IL $9,127
- United Digestive $6,000
- Virginia Mason Medical Center, WA $3,471
- Southern Star Research Institute LLC $125
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.